UK-based Hikma Pharmaceuticals’ wholly owned affiliate West-Ward Pharmaceuticals has signed an agreement with Vectura for the development of generic salmeterol product (VR730) for the US market. 

The long acting beta-agonists (LABA) generic salmeterol is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is delivered using Vectura’s new dry powder inhalation technology and device. 

According to IMS Health, sales of inhaled DPI and pMDI LABAs in the US totalled approximately $150m last year.

Under the agreement, Hikma will be responsible for the clinical development, manufacture and commercialisation of the product, while Vectura will complete the formulation development of the product, which will be funded by Hikma. 

"This builds on the strong relationship we have established through our programme for the development of generic Advair Diskus."

Vectura will initially receive $375,000 and potential further development, filing, approval and launch milestones up to an aggregate amount of $1.12m. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will also receive a share of future returns on the product, once Hikma recovers the costs of the clinical endpoint pivotal trial.

West-Ward Pharmaceuticals CEO Mike Raya said: “We are very pleased to be extending our partnership with Vectura. 

“This builds on the strong relationship we have established through our programme for the development of generic Advair Diskus. 

“By leveraging Hikma’s strong R&D, high-quality manufacturing and excellent commercial capabilities, we are successfully executing our pipeline development strategy for our US generics business and improving patient access to high-quality, affordable medicines.”